FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
...vel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of Fatty Acid Synthase (FAS) for use in Oncology. The fasgen
researchers have extensive experience studying the over-expression of FAS, an enzyme over-expressed in virtually all solid tumors. The inhibition of ...
FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
... BALTIMORE, March 26 /PRNewswire/ -- fasgen
Diagnostics, LLC is pleased
to report that results...pounds from FASgen, Inc., an affiliated company of fasgen
LLC, which makes FASi compounds inten...emoresistant and recurrent
Diagnostics, LLC and FASgen, Inc.: FASgen, Inc. is...
FASgen Announces New Research Discoveries in Lung Cancer
... BALTIMORE, Dec. 28 /PRNewswire/ -- fasgen
is pleased to report the
publication of important research results for lung...nds. In a long-standing
cooperation with The Johns Hopkins Oncology Center, fasgen
research into the selective inhibition of fatty acid synthase (FA...
FASgen Announces New Diagnostic Research Test for Steatohepatitis
... BALTIMORE, fasgen
Inc. announced it has successfully expanded the po...dle biopsy. While only for research use presently, fasgen
anticipates the opportunity for use of the non-inv.... FAS-Detect(TM) ELISA is a proprietary product of fasgen
Diagnostics LLC, an affiliated...
FASgen in Medical Technology
FASgen Announces a New Discovery in Obesity Research
... BALTIMORE, Dec. 21 /PRNewswire/ -- fasgen
is pleased to report the
publication of important ...AS89B, one of the Company's proprietary compounds. fasgen
is a leader in
the field of research into selectiv...8,
2007). This new discovery adds another tool for fasgen
to use, in addition
to FASi and GPATi compounds al...
FASgen Announces New Discovery for Treatment of Stroke
... BALTIMORE, Dec. 20 /PRNewswire/ -- fasgen
is pleased to announce the
recent publication of important results from research into a potential
treatment for stroke using one of FASgen's proprieta...
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
...n of FAS kills
the cancer cell, a result that has been recently replicated in a number of
labs and become the subject of a series of new publications. fasgen
developed a library of FASi compounds and has an extensive body of
intellectual property surrounding both the mechanism of action and uses for
FASgen in Biological Technology